Finding companies with the criteria you want isn’t always easy. You could spend hours searching ticker after ticker, only to find companies which aren’t worthy of your hard earned cash. An easier way to navigate through this is by using high quality stock screeners. Screening helps investors narrow down companies to invest in based on their ability to meet every criteria selected. Any company who misses even one of the criteria requirements will be filtered out.
Today, we’ve dug up two healthcare stocks using one of our premium screens known as “Zacks #1 Rank Uptrends”. Some of the metrics of this screen requires a stock to have an average daily trading volume of at least 100,000 shares over the last 20 days, a price change greater than 10% over the last 12 weeks, and a positive price change over the last week. We added an additional metric which allowed us to screen for stocks from the healthcare sector. Without any further ado, let’s take a look at what our modified premium screen has found for us today.This lets one easily choose ideal metrics. Screens are effective because they sift out bad stocks and only keep the cream of the crop in. It isn’t always easy to create an effective screen. Our Zacks Premium Screens have helped with this, bringing profits to many investors over time. Our predefined criteria are chosen carefully to capture special kinds of companies.
Corcept Therapeutics Inc-(CORT - Free Report)
Corcept Therapeutics is focused on developing and commercializing drugs which treat severe metabolic, psychiatric, and oncologic disorders. CORT is build around treating conditions that are associated with the steroid hormone known as cortisol. CORT is a Zacks Rank #1 (Strong Buy) and it has a market cap of $659 million.
Corcept has multiple drugs which are progressing through trial phases so that they can receive FDA approval. The company has one approved drug on the market known as Korlym. Korlym was made for treating hyperglycemia associated with Cushing’s syndrome, a rare but debilitating endocrine disorder.
The company reported results from its second quarter in early August. Over the quarter, revenues came in at $19.7 million, picking up by 65% compared to Q2 of 2015. The company is bullish on seeing further growth in sales from Korlym, and it has reiterated its 2016 sales guidance of $76-$81 million.
Over the last 12 weeks, Corcept’s share price has grown by about 12%, and over the last week alone, the stock has picked up about 5%. CORT has an “A” for Growth in our Style Scores. For this fiscal year, EPS and sales are forecasted to grow by 267% and 59% respectively. The pharmaceutical company has done well to surpass our earnings expectations over each of the last four quarters, and it is expected to yield a positive EPS of $0.05 this year, according to our consensus estimate.
CORCEPT THERAPEUTICS Revenue (Quarterly)
CryoLife Inc-(CRY - Free Report)
CryoLife develops and sells implantable living human tissues for use in cardiovascular, vascular, and orthopedic surgeries across the US, Canada, and Europe. The firm has multiple products which are approved for marketing in the US and abroad. CryoLife is a Zacks Rank #1 (Strong Buy) and it has a market cap of $609 million.
CryoLife has a range of products which include surgical adhesives, heart valves, grafts, and more. The company’s adhesive products (BioGlue and BioFoam) accounted for about two thirds of quarterly sales. Sales from these two products have increased, but their dominating presence in CryoLife’s portfolio has decreased, thanks to the company’s acquisition of On-X Technologies. On-X’s artificial heart valve helped in boosting the company’s overall quarterly revenue by $9.5 million. In the company’s Q2 quarterly earnings release, sales grew by about 33% compared to the same quarter last year. Sales came in at $47.1 million for the quarter.
CryoLife’s stock has been very momentous over the last three months. Shares have climbed 48% higher since CRY released its Q2 earnings results on the 25thof July. In the last week alone, shares have been trending upwards as well, pushing up 4% higher. Two months ago, our current year EPS consensus estimate forecasted earnings of $0.21 per share. Now, our consensus for this year estimates EPS of $0.34.
Bottom Line
One magical screening ingredient which can’t be overlooked is a Zacks Rank #2 (Buy) or better. The rank helps to find companies which look like dependable earnings candidates. In addition to this great metric, the Zacks Premium Screenshelp you to add other criteria to find the most superior investment choices. While this article outlined potential candidates from one screen, the Zacks Premium service gives you access to the “Zacks #1 Rank Uptrends” and 45 other premium screens designed to give you superior investment returns.
No comments:
Post a Comment